Two Sigma Advisers
IBIO icon

Two Sigma Advisers’s iBio IBIO Stock Holding History

Two Sigma Advisers’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-108,400
Closed -$209K – 1013
2025
Q4 		$209K Buy
+108,400
New +$148K ﹤0.01% 2110
2022
Q2 		– Sell
-145
Closed -$31K – 2755
2022
Q1 		$31K Buy
145
+47
+48% +$9.83K ﹤0.01% 2636
2021
Q4 		$27K Buy
+98
New +$37.4K ﹤0.01% 2531

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Two Sigma Advisers's IBIO Position: Q1 2026 in Review

Two Sigma Advisers sold out of iBio (IBIO) in Q1 2026, closing a stake of 108,400 shares — an estimated $209K sold.

Two Sigma Advisers first reported a position in IBIO in Q4 2021 and held it in 3 quarters. The position peaked at $209K in Q4 2025. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Two Sigma Advisers reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 108,400 iBio shares in Q1 2026, an estimated $209K.
  • Two Sigma Advisers first reported a position in iBio in Q4 2021 and held it in 3 quarters.
  • Two Sigma Advisers's iBio position peaked at $209K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.